Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

[1]  C. Contag,et al.  Targeting localized immune suppression within the tumor through repeat cycles of immune cell-oncolytic virus combination therapy. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[2]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[3]  D. Tindall,et al.  Noninvasive imaging and radiovirotherapy of prostate cancer using an oncolytic measles virus expressing the sodium iodide symporter. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  D. Kirn,et al.  Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer , 2009, Nature Reviews Cancer.

[5]  D. Sze,et al.  Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. , 2008, The Lancet. Oncology.

[6]  D. Kirn,et al.  Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. , 2007, The Journal of clinical investigation.

[7]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Galanis,et al.  Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress , 2007, Nature Clinical Practice Oncology.

[9]  Jiwon Kim,et al.  Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[10]  J. Bell,et al.  Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.

[11]  E. Reinherz,et al.  Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. , 2005, The Journal of clinical investigation.

[12]  B. Moss,et al.  Vaccinia Virus Intermediate Stage Transcription Is Complemented by Ras-GTPase-activating Protein SH3 Domain-binding Protein (G3BP) and Cytoplasmic Activation/Proliferation-associated Protein (p137) Individually or as a Heterodimer* , 2004, Journal of Biological Chemistry.

[13]  Eric P Tamm,et al.  CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. , 2004, AJR. American journal of roentgenology.

[14]  S. Libutti,et al.  Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[15]  D. Norwood,et al.  Smallpox and pan-Orthopox Virus Detection by Real-Time 3′-Minor Groove Binder TaqMan Assays on the Roche LightCycler and the Cepheid Smart Cycler Platforms , 2004, Journal of Clinical Microbiology.

[16]  M. Byrne,et al.  Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Law,et al.  Vaccinia virus motility. , 2003, Annual review of microbiology.

[18]  Lawrence M Wein,et al.  Validation and analysis of a mathematical model of a replication-competent oncolytic virus for cancer treatment: implications for virus design and delivery. , 2003, Cancer research.

[19]  L. Hartmann,et al.  Intraperitoneal therapy of ovarian cancer using an engineered measles virus. , 2002, Cancer research.

[20]  S. Libutti,et al.  Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. , 2001, Cancer research.

[21]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[22]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[23]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[24]  S Rozen,et al.  Primer3 on the WWW for general users and for biologist programmers. , 2000, Methods in molecular biology.

[25]  L. Eisenlohr,et al.  Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma , 1999, Cancer Gene Therapy.

[26]  Robert B Sim,et al.  Extracellular enveloped vaccinia virus is resistant to complement because of incorporation of host complement control proteins into its envelope. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Geoffrey L. Smith,et al.  Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. , 1997, The Journal of general virology.

[28]  N. Nissen,et al.  Clinical pharmacokinetic studies of a human haemopoietic growth factor, GM‐CSF , 1992, European journal of clinical investigation.

[29]  B. Moss,et al.  Vaccinia virus: a tool for research and vaccine development , 1991, Science.

[30]  Jerome L. Myers,et al.  Research Design and Statistical Analysis , 1991 .

[31]  B. Moss,et al.  Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype , 1985, Nature.

[32]  J. Bender,et al.  Phase I Trial , 1983 .